VYMADA FCT 49/51MG

About Sacubitril/Valsartan, marketed as Vymada, is a combination medication specifically designed for the treatment of chronic heart failure with reduced ejection fraction. It comprises a neprilysin inhibitor (sacubitril) and an angiotensin receptor blocker (valsartan). Sacubitril works by inhibiting the enzyme neprilysin, which leads to increased levels of natriuretic peptides. These peptides promote vasodilation, natriuresis, and diuresis, thereby reducing cardiac workload. Valsartan, on the other hand, blocks the angiotensin II type 1 receptor, counteracting the detrimental effects of angiotensin II, such as vasoconstriction and aldosterone secretion. This synergistic dual mechanism helps to significantly reduce the risk of cardiovascular death and heart failure hospitalization, while also improving symptoms and physical capacity in affected patients. It represents a significant advancement in heart failure management, often used as a replacement for ACE inhibitors or ARBs in suitable patients. Uses Treatment of chronic heart failure with reduced ejection fraction. To reduce the risk of cardiovascular death in heart failure patients. To decrease the incidence of heart failure hospitalizations. Management of symptomatic chronic heart failure. Directions For Use Take orally twice daily, as prescribed by your physician. Swallow the tablet whole with water, with or without food. Benefits Significantly reduces the risk of cardiovascular death. Decreases the rate of heart failure hospitalizations. Improves symptoms and quality of life for heart failure patients. Enhances physical capacity and exercise tolerance. Offers a novel, dual mechanism of action for heart failure. Provides comprehensive cardiovascular protection. Side Effects Hypotension (low blood pressure) Hyperkalemia (high potassium levels) Renal impairment (kidney problems) Angioedema (swelling under the skin) Cough Dizziness Fatigue Nausea Diarrhea Headache Anemia Syncope (fainting) Safety Measures Alcohol - Alcohol may exacerbate the hypotensive effects of Vymada; use with caution and monitor blood pressure. Pregnancy - Contraindicated in pregnancy due to potential fetal harm (renal dysfunction, oligohydramnios, fetal death). Breastfeeding - Not recommended during breastfeeding as it is unknown if it passes into breast milk and could harm the infant. Liver - Use with caution in patients with mild to moderate hepatic impairment; not recommended in severe hepatic impairment. Kidney - Requires dose adjustment in patients with moderate to severe renal impairment; monitor kidney function closely. Lung - Generally safe for use in patients with lung conditions, but monitor for cough, a known side effect. Disclaimer MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment. Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub. Our goal is to complement, not replace, the essential doctor-patient relationship.